Alterity Therapeutics (ATHE) Net Cash Flow (2009 - 2020)

Alterity Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at -$6.2 million in Q2 2020.

• On a quarterly basis, Net Cash Flow rose 36.76% year-over-year to -$6.2 million in Q2 2020; TTM through Jun 2020 was -$19.1 million, a 6.86% increase from a year earlier, with the FY2026 full-year figure at $2.9 million, up 100.0% from the prior year.
• Net Cash Flow was -$6.2 million for Q2 2020 at Alterity Therapeutics, down from $1.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $1.9 million in Q4 2019, with the low at -$9.8 million in Q2 2019.
• Average Net Cash Flow over 5 years is -$3.7 million, with a median of -$4.6 million recorded in 2017.
• The sharpest annual moves came in 2018 and 2019: Net Cash Flow plunged 444.27% in 2018, then surged 137.95% in 2019.
• Over 5 years, Net Cash Flow stood at -$598231.8 in 2016, then tumbled by 56.04% to -$933486.7 in 2017, then slumped by 444.27% to -$5.1 million in 2018, then soared by 137.95% to $1.9 million in 2019, then sank by 420.59% to -$6.2 million in 2020.
• The last three Net Cash Flow figures came in at -$6.2 million (Q2 2020), $1.9 million (Q4 2019), and -$9.8 million (Q2 2019), per Business Quant data.